CV Therapeutics, Inc. - 500 Beiträge pro Seite
eröffnet am 30.12.07 19:09:54 von
neuester Beitrag 03.09.08 11:54:16 von
neuester Beitrag 03.09.08 11:54:16 von
Beiträge: 10
ID: 1.136.809
ID: 1.136.809
Aufrufe heute: 0
Gesamt: 2.007
Gesamt: 2.007
Aktive User: 0
ISIN: US1266671049 · WKN: 912268
Feedback
Möchte hier nochmal einen Träät starten. Hab den Wert vor 8 Jahren mal besessen und will mal schauen ob und wie er sich vielleicht wieder entwikeln kann.
Sei doch froh dass du die Aktien nicht bis jetzt gehalten hast!
Die Firma macht (noch) ein sattes Minus, und solche Aktien kaufe ich grundsätzlich nicht.
Die Firma macht (noch) ein sattes Minus, und solche Aktien kaufe ich grundsätzlich nicht.
Antwort auf Beitrag Nr.: 32.901.569 von HuskyEnergy am 30.12.07 19:41:34Ja, schon klar, mir geht es zunächst um ein beleuchten des derzeitigen Geschäfts und den Blick auf das, was möglich sein könnte.
Fangen wir mal an ...
CV Therapeutics "buy"
Thursday, December 27, 2007 7:57:31 AM ET
Cantor Fitzgerald
NEW YORK, December 27 (newratings.com) - Analyst George Zavoico of Cantor Fitzgerald maintains his "buy" rating on CV Therapeutics Inc (CVTX.NAS). The target price is set to $40.
In a research note published this morning, the analyst mentions that the number of new, repeat and total Ranexa prescriptions declined by 4.3%, 6.7% and 5.8%, respectively, in the week ended December 14. The modest decline in prescriptions after two consecutive weeks of above-average growth represents a consolidation trend, according to the analyst. CV Therapeutics is expected to return to robust growth levels in early 2008, Cantor Fitzgerald adds.
CV Therapeutics "buy"
Thursday, December 27, 2007 7:57:31 AM ET
Cantor Fitzgerald
NEW YORK, December 27 (newratings.com) - Analyst George Zavoico of Cantor Fitzgerald maintains his "buy" rating on CV Therapeutics Inc (CVTX.NAS). The target price is set to $40.
In a research note published this morning, the analyst mentions that the number of new, repeat and total Ranexa prescriptions declined by 4.3%, 6.7% and 5.8%, respectively, in the week ended December 14. The modest decline in prescriptions after two consecutive weeks of above-average growth represents a consolidation trend, according to the analyst. CV Therapeutics is expected to return to robust growth levels in early 2008, Cantor Fitzgerald adds.
AP
CV Therapeutics Discloses Ranexa Sales
Tuesday January 8, 12:46 pm ET
CV Therapeutics Expects to Book $21 Million in 4th-Qtr From Sales of Angina Drug Ranexa
NEW YORK (AP) -- Biopharmaceutical company CV Therapeutics Inc. expects fourth-quarter net revenue of about $21 million from sales of its chronic angina drug, Ranexa, according to a Securities and Exchange Commission filing Tuesday.
CV Therapeutics also estimates that the company's operating expenses will be roughly $50 million to $55 million during the quarter, which is consistent with previously disclosed guidance.
The company said product and collaboration revenues will offset some of the operating expenses.
Ranexa is used to treat chronic angina, or chest pain, in patients whose use of alternative drugs has not produced adequate results. The company says the drug should be used in combination with other medications, including amlodipine, beta-blockers or nitrates.
CV Therapeutics shares gained 15 cents to $8.97 in afternoon trading.
CV Therapeutics Discloses Ranexa Sales
Tuesday January 8, 12:46 pm ET
CV Therapeutics Expects to Book $21 Million in 4th-Qtr From Sales of Angina Drug Ranexa
NEW YORK (AP) -- Biopharmaceutical company CV Therapeutics Inc. expects fourth-quarter net revenue of about $21 million from sales of its chronic angina drug, Ranexa, according to a Securities and Exchange Commission filing Tuesday.
CV Therapeutics also estimates that the company's operating expenses will be roughly $50 million to $55 million during the quarter, which is consistent with previously disclosed guidance.
The company said product and collaboration revenues will offset some of the operating expenses.
Ranexa is used to treat chronic angina, or chest pain, in patients whose use of alternative drugs has not produced adequate results. The company says the drug should be used in combination with other medications, including amlodipine, beta-blockers or nitrates.
CV Therapeutics shares gained 15 cents to $8.97 in afternoon trading.
Trading Spotlight
CV Therapeutics "overweight"
Wednesday, January 16, 2008 8:29:33 AM ET
Lehman Brothers
NEW YORK, January 16 (newratings.com) - In a research note published yesterday, analyst Jim Birchenough of Lehman Brothers maintains his "overweight" rating on CV Therapeutics Inc (CVTX.NAS). The target price is set to $29
Wednesday, January 16, 2008 8:29:33 AM ET
Lehman Brothers
NEW YORK, January 16 (newratings.com) - In a research note published yesterday, analyst Jim Birchenough of Lehman Brothers maintains his "overweight" rating on CV Therapeutics Inc (CVTX.NAS). The target price is set to $29
04.02.2008 22:07
CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology
PALO ALTO and SANTA ROSA, Calif., Feb. 4 /PRNewswire-FirstCall/ -- CV Therapeutics, (News) Inc. and Medlogics Device Corporation announced today that the companies have entered into an agreement under which Medlogics has licensed CV Therapeutics' proprietary biopolymer stent coating technology to develop a drug eluting stent (DES). CV Therapeutics received Medlogics stock and is entitled to development milestone payments, royalties and other potential payments on future sales of any products incorporating the technology.
Medlogics recently received a CE Mark from European regulatory authorities for its Cobalt Super Alloy (COBRA) stent and expects to launch the stent in Europe in the first quarter of 2008. Medlogics expects to utilize CV Therapeutics' biopolymer stent coating technology to develop a next- generation DES based on the COBRA stent platform.
Stents are small metal mesh devices which can be inserted into clogged blood vessels to reopen them. Commercially available stents with drugs such as paclitaxel or rapamycin in the coating have been shown to reduce the frequency of restenosis, which is the reclosure of the vessel after the stent has been implanted. Based on preclinical data, CV Therapeutics' proprietary biopolymer stent coating technology could potentially improve the performance of these drug eluting stents by controlling the drug release rate more precisely. The proprietary manufacturing process used to create the biopolymer may limit or reduce cracking and peeling following implantation of the stent.
"The novel architecture and thin strut design of our COBRA stent platform, combined with CV Therapeutics' unique bioerodible technology, provide Medlogics with an outstanding opportunity to develop innovative improved products to meet the needs of interventional cardiologists and their patients," said Richard L. Klein, president of Medlogics. "Cardiovascular disease remains the nation's greatest killer, and we are committed to providing new technologies that can improve quality of life for these patients."
"Licensing our proprietary biopolymer stent coating technology to Medlogics with their best-in-class stent design allows CV Therapeutics to potentially generate revenues from future milestones and product sales and to continue focusing on maximizing the potential for Ranexa, regadenoson and our pipeline of pharmaceutical therapies," said Louis G. Lange, CV Therapeutics chairman and chief executive officer.
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.
CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.
CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.
About Medlogics
Founded in August 2002, Medlogics is a California corporation based in Santa Rosa, California. Medlogics has vertically integrated drug eluting coating, stent and catheter research, development and manufacturing at this facility. The company plans to launch its COBRA stent in Europe in the 1st quarter of 2008.
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.
... et kütt, et kütt
CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology
PALO ALTO and SANTA ROSA, Calif., Feb. 4 /PRNewswire-FirstCall/ -- CV Therapeutics, (News) Inc. and Medlogics Device Corporation announced today that the companies have entered into an agreement under which Medlogics has licensed CV Therapeutics' proprietary biopolymer stent coating technology to develop a drug eluting stent (DES). CV Therapeutics received Medlogics stock and is entitled to development milestone payments, royalties and other potential payments on future sales of any products incorporating the technology.
Medlogics recently received a CE Mark from European regulatory authorities for its Cobalt Super Alloy (COBRA) stent and expects to launch the stent in Europe in the first quarter of 2008. Medlogics expects to utilize CV Therapeutics' biopolymer stent coating technology to develop a next- generation DES based on the COBRA stent platform.
Stents are small metal mesh devices which can be inserted into clogged blood vessels to reopen them. Commercially available stents with drugs such as paclitaxel or rapamycin in the coating have been shown to reduce the frequency of restenosis, which is the reclosure of the vessel after the stent has been implanted. Based on preclinical data, CV Therapeutics' proprietary biopolymer stent coating technology could potentially improve the performance of these drug eluting stents by controlling the drug release rate more precisely. The proprietary manufacturing process used to create the biopolymer may limit or reduce cracking and peeling following implantation of the stent.
"The novel architecture and thin strut design of our COBRA stent platform, combined with CV Therapeutics' unique bioerodible technology, provide Medlogics with an outstanding opportunity to develop innovative improved products to meet the needs of interventional cardiologists and their patients," said Richard L. Klein, president of Medlogics. "Cardiovascular disease remains the nation's greatest killer, and we are committed to providing new technologies that can improve quality of life for these patients."
"Licensing our proprietary biopolymer stent coating technology to Medlogics with their best-in-class stent design allows CV Therapeutics to potentially generate revenues from future milestones and product sales and to continue focusing on maximizing the potential for Ranexa, regadenoson and our pipeline of pharmaceutical therapies," said Louis G. Lange, CV Therapeutics chairman and chief executive officer.
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.
CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.
CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.
About Medlogics
Founded in August 2002, Medlogics is a California corporation based in Santa Rosa, California. Medlogics has vertically integrated drug eluting coating, stent and catheter research, development and manufacturing at this facility. The company plans to launch its COBRA stent in Europe in the 1st quarter of 2008.
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.
... et kütt, et kütt
12.02.2008 08:04
CV Therapeutics Inc.: overweight (Lehman Brothers Inc.)
Rating-Update:
New York (aktiencheck.de AG) - Die Analysten von Lehman Brothers stufen die Aktie von CV Therapeutics (ISIN US1266671049 (News)/ WKN 912268) unverändert mit "overweight" ein. Das Kursziel werde bei 29 USD gesehen. (12.02.2008/ac/a/u)
Analyse-Datum: 12.02.2008
CV Therapeutics Inc.: overweight (Lehman Brothers Inc.)
Rating-Update:
New York (aktiencheck.de AG) - Die Analysten von Lehman Brothers stufen die Aktie von CV Therapeutics (ISIN US1266671049 (News)/ WKN 912268) unverändert mit "overweight" ein. Das Kursziel werde bei 29 USD gesehen. (12.02.2008/ac/a/u)
Analyse-Datum: 12.02.2008
Hab ich so auch noch nicht erlebt, dass die FDA einen Zulassungstermin "verpennt". Angeblich wegen Mangel an Leuten?!
Ist ne seltsame Behörde.
Allg. sind Biotechs im Moment ziemlich am Arsch. Da sind sehr wenige Kandidaten mit aussichtsreichen Wirkstoffen im Orbit unterwegs. CTVX gehört dazu und mal sehen wie das hier ausgeht.
Ist ne seltsame Behörde.
Allg. sind Biotechs im Moment ziemlich am Arsch. Da sind sehr wenige Kandidaten mit aussichtsreichen Wirkstoffen im Orbit unterwegs. CTVX gehört dazu und mal sehen wie das hier ausgeht.
Ich denke es ist an der Zeit sich wieder mit diesem Wert zu beschäftigen 
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -1,33 | |
| +23,94 | |
| -2,70 | |
| +0,23 | |
| +0,48 | |
| -3,49 | |
| -0,19 | |
| -0,76 | |
| -2,01 | |
| -0,77 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 240 | ||
| 98 | ||
| 81 | ||
| 78 | ||
| 75 | ||
| 52 | ||
| 41 | ||
| 38 | ||
| 36 | ||
| 33 |
